February 12, 2018

Biostage names regenerative medicine expert to board

Charles Cox.

Holliston biotech Biostage has appointed another medical professional to its scientific advisory board as the company continues its makeover following a near bankruptcy position just months ago.

Charles Cox, director of the children's regenerative medicine program at University of Texas Health McGovern Medical School, was appointed to the board.

Since a $4.2-million investment largely from a group of Chinese investors in the fall, the company has begun a shift to focus on developing bioengineered organ implants to treat conditions of the throat in children.

Cox's experience in pediatric, surgical, cell therapy and cell-based tissue engineering make him particularly well-suited to help guide the company's scientific ventures, said board Co-Chairman Stephen Badylak.

The company already has a relationship with Cox's program. In August, the company announced the use of an esophageal implant in a patient at the University of Texas Health Science Center.

Cox joins Badylak, Joseph Vacanti, and Christine Finck, the last of whom is executive vice president and surgeon-in-chief at Connecticut Children's Medical Center.

Finck was appointed to the board last month, after her hospital invested $100,000 into the company.

"Our technology's ability to attract this prestigious group of experts to our Scientific Advisory Board is a testament to our technology's potential," said Biostage CEO Jim McGorry.

Read more

Biostage awarded up to $1.7M grant for preclinical study

Biostage lands $1M investment

Biostage names Chinese investor as board chairman

Biostage appoints children's hospital surgeon to science board

Biostage's science perseveres through dire financial straits

Biostage closes $4.2M investment with Chinese group, Conn. hospital

Biostage combines stock 20:1 to satisfy $4M private investor

Biostage scores $4M private investment, eyes turnaround

Biostage delisting effective Dec. 18

Biostage misses 3Q filing deadline due to financial woes

Biostage lays off 71% of workforce after delisting

Holliston biotech delisted from NASDAQ

Biostage completes successful human implant

Biostage announces $3.1M agreement with investor

Biostage in acquisition talks

Biostage failed to meet NASDAQ requirements

Biostage running short on cash with IND looming


Type your comment here:

Today's Poll Would your company consider changing its name or brand if it had a connection to an undesirable event or ideology?<>
Most Popular on Facebook
Copyright 2017 New England Business Media